Granahan Investment Management LLC Trims Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Granahan Investment Management LLC lessened its stake in shares of Certara, Inc. (NASDAQ:CERT) by 20.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 239,224 shares of the company’s stock after selling 63,257 shares during the quarter. Granahan Investment Management LLC’s holdings in Certara were worth $2,548,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC raised its position in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after buying an additional 2,509 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after acquiring an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. purchased a new position in shares of Certara during the 4th quarter worth $47,000. Blue Trust Inc. boosted its holdings in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after purchasing an additional 822 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd grew its position in shares of Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after purchasing an additional 3,656 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

CERT has been the topic of a number of research analyst reports. Barclays raised Certara from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $11.00 to $14.00 in a research note on Thursday. Stephens reissued an “overweight” rating and issued a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. William Blair reaffirmed a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. KeyCorp lifted their price target on shares of Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, April 16th. Finally, Robert W. Baird upped their price objective on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, April 11th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Certara presently has an average rating of “Moderate Buy” and an average target price of $15.67.

Certara Price Performance

Certara stock opened at $11.98 on Friday. The firm has a fifty day moving average of $11.67 and a 200-day moving average of $11.67. The firm has a market capitalization of $1.94 billion, a P/E ratio of -59.90, a PEG ratio of 9.29 and a beta of 1.57. Certara, Inc. has a 52-week low of $8.64 and a 52-week high of $17.76. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. The business had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company’s revenue was up 9.7% on a year-over-year basis. During the same period last year, the business posted $0.10 EPS. As a group, analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.